

AOI Medical, Inc. Completes Enrollment for Its Sixty (60) Patient Ascendx™VCF Reduction System Clinical Trial

FDA Approval And Market Launch Anticipated For First Quarter 2010

London, UK, 7 September 2009 - [AOI Medical, Inc.](#) (the “Company” or “AOI”) (AIM: AOI), a medical device company focusing on innovative orthopaedic medical devices for the spine and trauma markets, has successfully completed enrollment for the sixty (60) patient clinical trial of its Ascendx™ Vertebral Compression Fracture (“VCF”) Reduction System (“Ascendx™”). The trial was initiated in June 2008 in eight sites across the United States.

The primary end point of the trial was acute procedural success defined as successful device deployment, cement delivery, and device withdrawal. The data from the trial will be used as clinical support for the Company’s 510(k) submission to the FDA in relation to Ascendx™. With the completion of the clinical trial, the Company believes it remains on track for FDA approval and market launch in the United States in the first quarter of 2010.

“While results are still in the process of being evaluated, we are pleased with the data and patient outcomes we have seen from the clinical trial thus far,” said Dr. Achecar, Chairman of the Company’s clinical advisory board.

William J. Christy, CEO of AOI, said: “We are delighted to have reached this very important milestone in our Company history. The Ascendx™ system was designed to provide notable improvements in the way physicians have traditionally treated VCFs and we look forward to updating our shareholders as we move toward approval and the introduction of the Ascendx™ product into the marketplace.”

For more news and information on AOI Medical, Inc., please visit www.IRGnews.com/coi/AOI where you can find a fact sheet on the company, investor presentations, and more.

About Ascendx™

Ascendx™ is an investigational device which comprises a set of tools specifically designed for use in the treatment of painful pathological fractures of the vertebral body that may result from osteoporosis, benign lesions and/or malignant lesions such as metastatic cancers and myeloma. Ascendx™ comprises two main instruments: a cutting device that creates a cavity in cancellous bone, and a reduction device that is used to restore the height of the fractured vertebra and which can deliver and contain the bio-material (bonding agent) in the cavity. The set of tools is designed to offer a potential enhancement over current techniques. Ascendx™ is an investigational device limited to investigational use in the ongoing IDE study in the United States.

Ascendx™ presents an attractive market opportunity. The size of the market is estimated to be in the region of USD700 million annually, rising to over USD900 million by 2012 (source: CRT Capital, LLC 2008).

Background to AOI Medical, Inc.

AOI is a medical device company focusing on the development and commercialisation of innovative orthopaedic medical devices for the spine and trauma markets. It is progressing the development of three separate technology platforms: Ascendx™ VCF Reduction System, BAMF Trauma and Cervical Plate. Further information can be found at www.aoimedical.net

Enquiries:

AOI Medical, Inc.

William J. Christy, CEO

Tel: +1 407 770 1800

Numis Securities Limited

Nominated Adviser: Michael Meade / Brent Nabbs

Corporate Broking: David Poutney

Tel: +44 (0) 20 7260 1000

The Investor Relations Group

Erika Moran/Tom Caden

Public Relations: Susan Morgenbesser

Tel: +1 212 825 3210

Background to AOI Medical, Inc.

AOI is a medical device company focusing on the development and commercialisation of innovative orthopaedic medical devices for the spine and trauma markets. It is progressing the development of three separate technology platforms: Ascendx™ VCF Reduction System, BAMF Trauma and Cervical Plate. Further information can be found at www.aoimedical.net